Next Article in Journal
Whole-Body Magnetic Resonance Tomography and Whole-Body Computed Tomography in Pediatric Polytrauma Diagnostics—A Retrospective Long-Term Two-Center Study
Next Article in Special Issue
Severe Liver Damage in an Obese Patient: Onset of Celiac Disease or Overlap Syndrome?
Previous Article in Journal
Accurate Detection of Alzheimer’s Disease Using Lightweight Deep Learning Model on MRI Data
Previous Article in Special Issue
Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 7
10.3390/diagnostics13071217
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Presence of KIR2DL2/S2, KIR2DL5, and KIR3DL1 Molecules in Liver Transplant Recipients with Alcoholic Cirrhosis Could Be Implicated in Death by Graft Failure

by
Raquel Morales
1,
José Miguel Bolarín
1,
Manuel Muro
2,*,† and
Isabel Legaz
1,*,†
1
Department of Legal and Forensic Medicine, Biomedical Research Institute (IMIB), Regional Campus of International Excellence “Campus Mare Nostrum”, Faculty of Medicine, University of Murcia, 30100 Murcia, Spain
2
Immunology Service, Instituto Murciano de Investigación Biosanitaria (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), 30120 Murcia, Spain
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Diagnostics 2023, 13(7), 1217; https://doi.org/10.3390/diagnostics13071217
Submission received: 12 February 2023 / Revised: 15 March 2023 / Accepted: 21 March 2023 / Published: 23 March 2023
(This article belongs to the Special Issue Diagnosis of Liver Disease)
Browse Figures
Versions Notes

Abstract

:
Background: The second-most frequent diagnosis among patients receiving liver transplants (LTs) is alcoholic liver disease. The multifactorial pathophysiology of alcoholic liver disease depends on the innate immune system and the inflammatory cascade. According to recent studies on these receptors, killer-cell immunoglobulin-like receptors (KIRs) may be involved in sepsis, liver rejection, and virus relapse. We aimed to investigate the impact of preclinical issues like ascites and encephalopathy and KIR genetic traits on death from sepsis, multiorgan failure (MF), and graft failure (GF) in AC patients undergoing LTs. Methods: We retrospectively reviewed 164 consecutive and deceased Caucasian AC patients who underwent LTs. Pre-transplant complications, cause of death, and patient survival were analyzed. Genomic DNA was taken from peripheral blood, and PCR-SSO was used for genotyping KIR. Results: Compared to GF patients, there was a statistically significant increase in the frequency of KIR2DL2+ (75.8% vs. 51.2%; p = 0.047). Another increase in frequency was also observed in KIR2DS2+ in sepsis compared to the GF group (51.2% vs. 43.7%; p = 0.018). In patients who passed away from MF, a decrease in KIR2DL5+ was observed in AC patients with and without encephalopathy (p = 0.018). The frequency of KIR3DL1+ in the AC patients significantly increased the mortality from sepsis (p = 0.045), which was confirmed by multivariate logistic regression. The frequency of KIR3DL1+ in the AC patients significantly increased the mortality from sepsis (p = 0.012) and was confirmed by multivariate logistic regression. KIR2DS1+ and KIR2DS4+ showed increased mortality due to GF compared to patients without these genes (p = 0.011 and 0.012, respectively). However, this fact was confirmed only for KIR2DS1+ by multivariate logistic Cox regression. Conclusions: The presence of the KIR2DL2/S2+, KIR2DL5+, and KIR3DL1+ genes increases the frequency of death from multiple organ failure or graft failure. Our findings highlight the AC patient’s vulnerability to a LT during hospitalization. Following the transplant and outside of it, we adopt essential preventive measures to create a routine healthcare screening to enhance and modify treatments to increase survival.

1. Introduction

The second-most frequent diagnosis among patients receiving liver transplants (LTs) is alcoholic liver disease [1,2,3]. Since transplanted AC patients now have a higher survival rate, this liver condition is one of the best indications for LTs [2,4,5]. Despite this improvement, patients should have a thorough post-transplant risk assessment for rejection, virus recurrence, and alcoholic relapse to make extreme efforts to avoid patient death [1,6,7].
Much research has not been performed on the clinical and molecular mechanisms that lead to liver graft loss or death in AC patients, but it has been widely accepted that various factors can contribute to these outcomes [2,8,9,10]. Immune causes of transplant malfunction and death are classically known [11,12,13]. Immune cells are critical for liver graft rejection and patient survival [11,14,15,16,17]. The role of the innate immune system and the inflammatory cascade in the multifactorial pathophysiology of alcoholic liver disease (ALD) is crucial [14,15,18,19,20,21]. Natural killer (NK) cells are thought to be important in the pathogenesis of liver inflammation and injury, as well as the control of viral hepatitis, liver fibrosis, and liver tumorigenesis, according to an increasing number of studies from the past ten years [22,23,24]. A better understanding of the pathogenesis of liver disease has revealed new therapeutic targets for treating this condition, thanks to the characterization of NK cell functions [25]. NK cell immune responses are regulated by a balance of activating and inhibitory signals transmitted by cell surface receptors [26]. According to recent studies, KIRs may be involved in sepsis [27,28], liver rejection [2], and virus relapse [10].
Different studies analyze the relationship between NK cells and their KIRs and find a higher incidence of certain forms of cancer and infections in chronic alcoholics [20,29,30].
A delicate balancing act regulates NK cell function between specific interactions between membrane receptors, including KIRs and their ligands, and human leukocyte antigen (HLA) class I molecules [31]. It is still unknown what leads to the deaths and survival of AC patients receiving LTs.
We aimed to investigate the influence of preclinical complications such as ascites and encephalopathy and KIR genetic characteristics on death due to sepsis, multiorgan failure (MF), and graft failure (GF) in patients with CA undergoing LTs to develop preventive actions and improve and/or modify treatments to increase the survival of the transplanted patient.

2. Material and Methods

2.1. Enrollment of Patients

The University Clinic Hospital “Virgen de la Arrixaca” in the Murcia Region (Spain) performed LTs on 164 consecutive deceased Caucasian AC patients. The medical records of these patients were retrospectively reviewed.
The mean pre-transplant age for all patients analyzed was 54.3 ± 6.9 years (mean years, standard deviation, SD). The inclusion criteria included primary LTs without a history of additional organ transplantation, ABO compatibility, HIV neglect, retransplants, and transplants carried out in patients who lost grafts within the first week following the transplant.
Informed consent was obtained in all cases. The institutional ethical committee approved the study protocol in accordance with the Declaration of Helsinki’s Principles. This study was carried out in accordance with the Helsinki Declaration, and the HCUVA Ethics Committee approved the protocol (PI15/01370). Current regulations ensure the confidentiality of personal data and automated processing.

2.2. Alcoholic Cirrhosis Diagnostic Criteria

Clinical, radiologic, and biochemical markers were used to diagnose AC [32]. Before being diagnosed with cirrhosis, AC patients had a history of drinking alcohol above what was considered safe. The opinions of their relatives were considered in the case of a negative self-report of alcohol intake.
The diagnosis was made after a routine scan, ultrasound test, or clinical examination because the early stages of cirrhosis typically have no symptoms. When symptoms like ascites, upper gastrointestinal hemorrhage, and encephalopathy started to appear during the second stage of decompensated cirrhosis, the illness was, in some cases, not discovered until then. Specific analytical and imaging methods were used to confirm cases of probable cirrhosis.
Additionally, pretransplant ascites and encephalopathy were identified [9,33,34], and it was noted in the clinical history whether they were present.

2.3. Diagnosis of Immune Suppression and Rejection

With tacrolimus or cyclosporine as the initial dose, standard triple-drug therapy was administered to all patients, adjusted to maintain the recommended immunosuppressive levels. The Banff scheme and clinical, biochemical, and histological criteria were used to diagnose and grade rejection [33,34]. Liver rejection episodes were treated as previously reported [9,11].

2.4. Causes of Mortality in Alcoholic Cirrhosis Patients

The main causes of mortality, MF, GF, and sepsis were analyzed in AC patients according to previous studies [35] until three years after their LTs. Medico-legal autopsies or medical death certificates were used to determine the critical causes of AC death. The principal causes of death are those reported by the physician engaged in the patient’s care.
Other causes of death (cardiac arrest, digestive bleeding, metastasis, edema lung, metastasis, pancreatitis, pneumonia, primary dysfunction, and viral relapse) could not be analyzed individually in this study due to its limited sample size, which does not allow a deeper statistical analysis of the association.

2.5. KIR Genotyping

Peripheral blood samples were used in this study. Following the manufacturer’s instructions, the genomic DNA was extracted using the QIAamp DNA Blood Mini Kit from QIAGEN in Hilden, Germany.
Luminex® technology’s sequence-specific oligonucleotides (PCR-SSO) were used for genotyping KIR in all patients (n = 164) (TepnelLifecodes, Stamford, CT, USA). This technology activates the KIR2DS1-S5 and KIR3DS1 genes by recognizing inhibitory KIR2DL1-3, KIR3DL1-3, and KIR2DL4. Additionally, we discovered the pseudogenes KIR2DP1 and KIR3DP1. Activating KIRs (aKIR) have a short cytoplasmic tail and no ITIM motif, whereas inhibitory KIRs (iKIR) have a long cytoplasmic tail and at least one immunoreceptor tyrosine-based inhibitory motif (ITIM) [1,2]. There is one KIR2DL4 gene, six iKIR (KIR3DL1-3, KIR2DL1-3) genes, six aKIR (KIR3DS1 and KIR2DS1-5) genes, and six aKIR (KIR3DS1 and KIR2DS1-5) genes.

2.6. Statistical Analyses

The findings and demographic data were entered into a database using SPSS version 27.0 software from Microsoft Corporation, Seattle, Washington (SPSS Software Inc., Chicago, IL, USA). All data are shown as a percentage or mean with a standard deviation. Categorized variables were compared between groups using the 2-tailed Fisher’s exact test and Pearson’s chi-squared test. Long-term AC patient survival differences were evaluated using the Kaplan–Meier and Log-rank tests at three years. A p > 0.05 was chosen as the statistically significant level. To assess relative risk, odds ratios (ORs) and 95% confidence intervals (CIs) were created. The factors connected to different death and survival causes were investigated using multivariate logistic regression analysis and multivariate Cox regression methods.

3. Results

3.1. Clinical and Sociodemographic Characteristics

Table 1 displays the entire cohort’s sociodemographic and primary clinical characteristics (n = 164; 91.4% men). Before the LTs, the entire cohort’s average age was 54.3 ± 6.9 (mean years and SD). Four categories were used to group the primary causes of death (sepsis, GF, MF, and others). Cardiovascular collapse, gastrointestinal bleeding, lung edema, metastasis, pancreatitis, pneumonia, primary dysfunction, and viral relapse are additional causes of death.

3.2. Frequency of KIR Genes in AC Patients with Different Causes of Death

The frequency of inhibitory and activator KIR genes (iKIR and aKIR, respectively) was examined in patients with various causes of death, as shown in Table 2.
In patients with MF compared to GF, there was a statistically significant increase in the frequency of KIR2DL2+ (75.8% vs. 43.7%; p = 0.018; OR = 0.247; 95% CI: 0.082–0.744). The analysis of the frequency of KIR2DS2+ revealed an increase that is statistically significant in MF compared to patients who died from GF (75.8% vs. 51.2%; p = 0.047, OR = 2.986; 95% CI: 1.037–8.594). On the other hand, an increase was also observed in KIR2DS2+ in sepsis compared to GF (51.2% vs. 43.7%; p = 0.018, OR = 4.041; 95% CI: 1.344–12.146).

3.3. Analysis of the Frequency of the Presence of KIR Genes in Causes of Death in Patients with and without Ascites

No statistically significant differences were found between the three causes of death in analyzing the frequency of ascites and the various KIR genes (Figure 1).

3.4. Analysis of the Frequency of KIR Genes in the Causes of Death of AC Patients with and without Encephalopathy

Figure 2 depicts an analysis of the frequency of KIR genes in causes of death in AC patients with and without encephalopathy.
Except for KIR2DS4+, KIR2DS3+, and the inhibitor gene KIR2DL1+, which were found to be increased in patients with encephalopathy, it was found that the frequency of most KIR genes (activators and inhibitors) decreased in patients with encephalopathy who died from MF (Figure 2A). In the cases of death due to sepsis in AC patients with encephalopathy, the frequency of most of the genes analyzed was increased, except for KIR2DS5+ (Figure 2B).
The analysis of the frequency of KIR genes in AC patients who died from GF with or without encephalopathy showed an increase in the frequency of most KIR genes (Figure 2B). We only obtained statistically significant differences in the case of the inhibitor gene KIR2DL5+. This finding was more representative of AC patients with encephalopathy who died by GF than those without encephalopathy (50% vs. 40.5 %, p = 0.018; OR = 2.124; 95% (IC: 1.264–2.146) who died both by GF. This increase in the frequency of KIR2DL5+ in encephalopathy patients could also be observed in patients who died from sepsis, but no significant differences were obtained in this case. However, when MF patients were compared to AC patients with encephalopathy and patients without encephalopathy, a decrease in KIR2DL5+ was found in these AC patients.
We also compared the various causes of death to the frequencies of the KIR genes. Only the inhibitor gene KIR3DL1+ showed statistically significant differences and was significantly higher in AC patients without encephalopathy or death from GF than sepsis or MF (97%, 68%, and 74%, p = 0.045). When comparing GF between AC patients with and without encephalopathy, differences in the frequency of KIR3DL1+ were also discovered (97% vs. 71%, p = 0.050; Figure 2D).
This interesting association was confirmed through multivariable logistic regression analysis (p = 0.044; Table 3).

3.5. Influence of iKIR on Time Elapsed between the Transplantation and the Cause of Death

Analysis was also performed on the impact of iKIR frequency on AC patient survival over the short- and long-term with various causes of death, including MF, sepsis, GF, and others (Figure 3). There was no statistically significant difference in the frequency of iKIRs (KIR2DL2, KIR2DL3, KIR2DL5, and KIR3DL1) for either the short- or long-term, nor for the examined causes of death (Figure 3A–D). No patients lacking the KIR2DL1 gene were present in the population being studied, making it impossible to analyze the influence of this gene. Differences in mortality were found by analyzing KIR3DL1 at three years (Figure 3E). The frequency of KIR3DL1+ in the AC patients significantly increased the mortality from graft failure (Log-rank, p = 0.012), and this fact was confirmed by multivariate logistic regression.

3.6. Influence of aKIR on Time Elapsed between Transplantation and Cause of Death

Additionally, the impact of aKIR frequency on AC patient survival over the short- and long-term with various causes of death (MF, sepsis, GF) was studied (Figure 4).
At three years post-transplant, the analysis of the frequency of aKIRs (KIR2DS2, KIR2DS5, and KIR3DS1) did not show any statistically significant difference for the causes of death analyzed (Figure 4B,E,F). KIR2DS1+ and KIR2DS4+ showed increased mortality due to GF compared to patients without these genes (Log-rank, p = 0.011 and 0.012, respectively). However, this fact was confirmed only for KIR2DS1+ by multivariate logistic Cox regression (Table 4). On the other hand, the KIR2DS3 analysis showed differences in mortality in patients who died due to other causes of death (Log-rank, p = 0.024) (Figure 4C).

4. Discussion

In this study, firstly, we characterized our patients by recording their main causes of death, their age, sex, and pre-transplant complications. Subsequently, we analyzed the frequency of the KIR genes in the different causes of death in the total population. Then, we performed the same analysis but divided the population according to whether or not they had a pre-transplant complication (ascites or encephalopathy) to see if they contributed to the KIR genes that cause death. Finally, we analyzed the possible influence of the KIR genes on the period elapsing between when the transplant is performed and when the patient dies. All of this is necessary for preventative actions that build a routine healthcare screening program to improve and modify treatments.
Previous studies [11,36] have observed that KIR genes are involved in rejecting transplanted organs. The KIR genes are a family of immunoreceptors found on the surface of NK cells, a type of white blood cell that plays an essential role in the immune system. These receptors recognize and bind to foreign antigens and initiate an immune response. KIR genes play an essential role in liver transplantation and are associated with an increased or decreased risk of acute liver allograft rejection modulated by NK cell activity.
The results obtained in this study are novel because, for the first time, the KIR genes present in the patients with AC have been related to their causes of death. A study by [35] analyzed the main causes of death without analyzing the patient’s genetics and their influence on the causes of death. Another study by [30] examined how the KIR genes affected the progression of the cirrhotic process in alcoholic patients and found that KIR2DL2 and KIR2DS5 had the opposite effect in patients older than 54 years with AC. In these patients, the presence of KIR2DL2 seemed to protect against AC, whereas the presence of KIR2DS5 seemed to promote the fibrotic process, especially in those without an associated viral infection. However, in most studies, the KIR genes are analyzed by focusing mainly on organ transplantation since these molecules are the membrane receptors of the NK cells of the innate immune system, whose ligands are the HLA-C molecules that are directly involved in the tolerance or rejection of grafted organs [11,36].
Our data show that most of the patients included in this study are male because women are underrepresented in the final stages of this disease, leading to loss of the liver and a liver transplant [1]. Data previously published by our group showed that alcoholic cirrhosis is a liver disease closely associated with men due to their high alcohol consumption [1,2].
Similar to the results of other studies, the frequency of death from MF after LTs in our study was 29% [37]. Patients with cirrhosis frequently experience MF, but the independent impact of the number or type of organ failures on LT outcomes is poorly understood [38]. Even in multiple organ failures, small retrospective studies have demonstrated that LT is feasible and has positive outcomes [38].
A previous study [11] observed that MF was the main cause of sudden death, with higher mortality during the first year after transplantation, followed by sepsis and GF, proving the vulnerability of AC patients in the hospital period after the transplant and outside. On the other hand, other studies corroborate the relationship between immunity and the cause of death [39,40].
According to a study, MF was the main factor in sudden death in AC patients receiving LTs, with higher mortality rates in the first year following transplantation. The results of this study also indicated that sepsis and GF were the primary killers [35]. However, additional research supports the link between immunity and the cause of death [39,40].
Leukocytes, monocytes/macrophages, and NK cells, which are the first line of the host’s defense and are specially equipped to survey their environment and respond swiftly to pathogen-derived threat signals through redistribution to the infection site in the body, are all cells of the innate immune system that express different receptors encoded by KIR genes. These cells serve as the first line of host defense [41,42,43].
In our study, the analysis of the frequency of KIR genes in the different causes of death showed that patients with alcoholic cirrhosis who died of multiple organ failure had a statistically significant increase in the frequency of the KIR2DL2+ and KIR2DS2+ genes. It should be noted that the increase in both genes corroborates the observations indicating that both genes are linked in our population [11,30], so it is impossible to know which of the two genes is involved in the development of multiple organ failure. Similar studies have found a statistically significant increase in the frequency of KIR2DL2+ and KIR2DS2+ genes in multiple organ damage patients with systemic lupus erythematosus [44] and systemic sclerosis [45].
In our study, the analysis of the relationship between the main causes of death and the frequency of KIR genes in patients with ascites and encephalopathy did not show statistically significant differences that could demonstrate an increase or decrease in susceptibility to a specific death cause, except for KIR3DL1. Patients without encephalopathy in AC showed increased GF frequency compared to patients with encephalopathy, corroborated by multivariate logistic regression analysis.
In this sense, KIR3DL1 is a highly polymorphic receptor that binds to groups of HLA-A and HLA-B allotypes that express the Bw4 epitope. The difference in allotypes of KIR3DL1 expresses itself at various stages. A typical allelic variant mainly encodes an activating rather than an inhibitory receptor (KIR3DS1) [46]. This fact could explain the results obtained in our study, which indicate that the allelic variants of this gene should be studied shortly.
Additionally, grade III/IV encephalopathy in patients with acute liver failure may progress to cerebral edema, a potentially fatal complication [47]. According to Bernal et al. [48], the prevalence of MF as a cause of death has increased, while clinical cerebral edema associated with acute liver failure has generally decreased. The incidence of cerebral edema may be much more common in areas where transplantation is less common.
On the other hand, analysis of how the KIR genes affected the causes of death in AC patients once again revealed that KIR3DL1 impacted GF patient mortality. This influence could be seen both immediately and over time, and Cox’s regression multivariable analysis supported this. Three years after the transplant, it was also noted that the activator genes KIR2DS1 and KIR2DS4 impacted mortality.
According to Legaz et al. [10], the presence of KIR2DL3+ and KIR2DS1+ in patients increased AR incidence when donor C2 ligands were present simultaneously. However, they did not examine how different causes of death affected the likelihood of survival. Everything thus points to how aKIRs can affect GF and patient mortality.
The main limitation of our study is the limited sample size of other causes of death (cardiac arrest, digestive bleeding, metastasis, edema lung, metastasis, pancreatitis, pneumonia, primary dysfunction, and viral relapse), which could not be analyzed individually in this study due to its small sample size that does not allow a deeper statistical analysis of association. However, we cannot discard potential influence in future similar studies with larger cohorts and/or extended analysis periods. Despite all these limitations, our data are statistically robust, with promising diagnostic implications achieved in this study.

5. Conclusions

In conclusion, our results show how the presence of the KIR2DL2/S2+, KIR2DL5+, and KIR3DL1+ genes in the patient could increase the frequency of death from multiple organ failure or graft failure. Our findings demonstrate the AC patient’s susceptibility to LT inside and outside the hospital following the transplant. To improve and modify medical treatments for these patients to increase their short- and long-term survival, close medical monitoring and searching for biomarkers that indicate vulnerability to a specific cause of death are essential. In order to prevent death and enhance AC patient survival, it would be necessary to adhere to a protocol to avoid septic symptoms and GFs.

Author Contributions

Conceptualization, M.M. and I.L.; Methodology, R.M., J.M.B., M.M. and I.L.; Software, J.M.B., M.M. and I.L.; Validation, J.M.B., M.M. and I.L.; Formal analysis, R.M., J.M.B., M.M. and I.L.; Investigation, R.M., J.M.B., M.M. and I.L.; Resources, J.M.B., M.M. and I.L.; Data curation, J.M.B., M.M. and I.L.; Writing—original draft, R.M., M.M. and I.L.; Writing—review & editing, M.M. and I.L.; Visualization, M.M. and I.L.; Supervision, I.L.; Project administration, I.L.; Funding acquisition, I.L. All authors have read and agreed to the published version of the manuscript.

Funding

Our work was possible thanks to support from the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness. Grants number P19/01194 and co-funding the European Union with the European Fund for Regional Development (FEDER) with the principle of “A manner to build Europe”.

Institutional Review Board Statement

HCUVA Ethics Committee approved the protocol (PI15/01370).

Informed Consent Statement

Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement

Data is unavailable due to privacy or ethical restrictions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Legaz, I.; Navarro Noguera, E.; Bolarín, J.M.; Campillo, J.A.; Moya, R.; Luna, A.; Muro, M. Patient Sex in the Setting of Liver Transplant in Alcoholic Liver Disease. Exp. Clin. Transpl. 2018, 17, 355–362. [Google Scholar] [CrossRef] [PubMed]
  2. Legaz, I.; Navarro-Noguera, E.; Bolarín, J.M.; García-Alonso, A.M.; Luna Maldonado, A.; Mrowiec, A.; Campillo, J.A.; Gimeno, L.; Moya-Quiles, R.; Álvarez-López, M.D.R.; et al. Epidemiology, Evolution, and Long-Term Survival of Alcoholic Cirrhosis Patients Submitted to Liver Transplantation in Southeastern Spain. Alcohol. Clin. Exp. Res. 2016, 40, 794–805. [Google Scholar] [CrossRef] [PubMed]
  3. Lucey, M.R. Liver transplantation for alcoholic liver disease. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 300–307. [Google Scholar] [CrossRef] [PubMed]
  4. Singal, A.K.; Anand, B.S. Recent trends in the epidemiology of alcoholic liver disease. Clin. Liver Dis. 2013, 2, 53–56. [Google Scholar] [CrossRef]
  5. Burra, P.; Senzolo, M.; Adam, R.; Delvart, V.; Karam, V.; Germani, G.; Neuberger, J. Liver Transplantation for Alcoholic Liver Disease in Europe: A Study from the ELTR (European Liver Transplant Registry). Am. J. Transplant. 2010, 10, 138–148. [Google Scholar] [CrossRef]
  6. Arab, J.P.; Izzy, M.; Leggio, L.; Bataller, R.; Shah, V.H. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat. Rev. Gastroenterol. Hepatol. 2021, 19, 45–59. [Google Scholar] [CrossRef]
  7. Legaz, I.; Muro, M. Optimizing strategies to reduce alcohol consumption and relapses, improving abstinence in liver transplant recipients. Hepatobiliary Surg. Nutr. 2022, 11, 153–155. [Google Scholar] [CrossRef]
  8. Vikhert, A.M.; Tsiplenkova, V.G.; Cherpachenko, N.M. Alcoholic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 1986, 8, 3A–11A. [Google Scholar] [CrossRef] [Green Version]
  9. Legaz, I.; Bolarin, J.M.; Campillo, J.A.; Moya, R.M.; Luna, A.; Osuna, E.; Minguela, A.; Sanchez-Bueno, F.; Alvarez, M.R.; Muro, M. Pretransplant ascites or encephalopathy and their influence on survival and liver graft rejection in alcoholic cirrhosis disease. Arch. Med. Sci. 2018, 17, 682–693. [Google Scholar] [CrossRef]
  10. Legaz, I.; López-Álvarez, M.R.; Campillo, J.A.; Moya-Quiles, M.R.; Bolarín, J.M.; de la Peña, J.; Salgado, G.; Gimeno, L.; García-Alonso, A.M.; Muro, M.; et al. KIR gene mismatching and KIR/C ligands in liver transplantation: Consequences for short-term liver allograft injury. Transplantation 2013, 95, 1037–1044. [Google Scholar] [CrossRef]
  11. Crispe, I.N. Immune tolerance in liver disease. Hepatology 2014, 60, 2109–2117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Sood, S.; Testro, A.G. Immune monitoring post liver transplant. World J. Transplant. 2014, 4, 30–39. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Ilyas, J.A.; O’Mahony, C.A.; Vierling, J.M. Liver transplantation in autoimmune liver diseases. Best Pract. Res. Clin. Gastroenterol. 2011, 25, 765–782. [Google Scholar] [PubMed]
  14. Wu, Z.; Han, M.; Chen, T.; Yan, W.; Ning, Q. Acute liver failure: Mechanisms of immune-mediated liver injury. Liver Int. 2010, 30, 782–794. [Google Scholar]
  15. Harmon, C.; Sanchez-Fueyo, A.; O’Farrelly, C.; Houlihan, D.D. Natural Killer Cells and Liver Transplantation: Orchestrators of Rejection or Tolerance? Am. J. Transplant. 2016, 16, 751–757. [Google Scholar] [CrossRef]
  16. Kroemer, A.; Xiao, X.; Degauque, N.; Edtinger, K.; Wei, H.; Demirci, G.; Li, X.C. The Innate NK Cells, Allograft Rejection, and a Key Role for IL-15. J. Immunol. 2008, 180, 7818–7826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Li, S.W.; Cai, Y.; Mao, X.L.; He, S.Q.; Chen, Y.H.; Yan, L.L.; Zhou, J.J.; Song, Y.Q.; Ye, L.P.; Zhou, X. Bin The Immunomodulatory Properties of Mesenchymal Stem Cells Play a Critical Role in Inducing Immune Tolerance after Liver Transplantation. Stem Cells Int. 2021, 2021, 6930263. [Google Scholar] [CrossRef]
  18. Szabo, G.; Petrasek, J.; Bala, S. Innate Immunity and Alcoholic Liver Disease. Dig. Dis. 2012, 30, 55–60. [Google Scholar] [CrossRef] [Green Version]
  19. Gao, B.; Seki, E.; Brenner, D.A.; Friedman, S.; Cohen, J.I.; Nagy, L.; Szabo, G.; Zakhari, S. Innate immunity in alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300, 516–525. [Google Scholar] [CrossRef]
  20. Jeong, W.-I.; Gao, B. Innate immunity and alcoholic liver fibrosis. J. Gastroenterol. Hepatol. 2008, 23, S112–S118. [Google Scholar] [CrossRef]
  21. Miller, A.M.; Horiguchi, N.; Jeong, W.I.; Radaeva, S.; Gao, B. Molecular Mechanisms of Alcoholic Liver Disease: Innate Immunity and Cytokines. Alcohol. Clin. Exp. Res. 2011, 35, 787–793. [Google Scholar] [PubMed] [Green Version]
  22. Tian, Z.; Chen, Y.; Gao, B. Natural killer cells in liver disease. Hepatology 2013, 57, 1654–1662. [Google Scholar] [PubMed] [Green Version]
  23. Ben-Eliyahu, S.; Page, G.G.; Yirmiya, R.; Taylor, A.N. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat. Med. 1996, 2, 457–460. [Google Scholar] [PubMed]
  24. Jeong, W.I.; Park, O.; Gao, B. Abrogation of the Antifibrotic Effects of Natural Killer Cells/Interferon-γ Contributes to Alcohol Acceleration of Liver Fibrosis. Gastroenterology 2008, 134, 248–258. [Google Scholar]
  25. Gao, B.; Bataller, R. Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterology 2011, 141, 1572–1585. [Google Scholar]
  26. Lanier, L.L. Natural killer cell receptor signaling. Curr. Opin. Immunol. 2003, 15, 308–314. [Google Scholar]
  27. Oliveira, L.M.; Portela, P.; Merzoni, J.; Lindenau, J.D.; Dias, F.S.; Beppler, J.; Graebin, P.; Alho, C.S.; Schwartsmann, G.; Dal-Pizzol, F.; et al. Reduced frequency of two activating KIR genes in patients with sepsis. Hum. Immunol. 2017, 78, 363–369. [Google Scholar]
  28. Oliveira, L.M.; Portela, P.; Merzoni, J.; Beppler, J.; Dias, F.S.; Graebin, P.; Alho, C.S.; Schwartsmann, G.; Dal-Pizzol, F.; Jobim, L.F.; et al. KIR gene haplotype A is associated with hospital mortality in patients with sepsis. Clin. Immunol. 2019, 200, 37–38. [Google Scholar] [CrossRef]
  29. Wei, Y.; Bingyu, W.; Lei, Y.; Xingxing, Y. The antifibrotic role of natural killer cells in liver fibrosis. Exp. Biol. Med. 2022, 247, 1235–1243. [Google Scholar]
  30. Legaz, I.; Bolarín, J.M.; Navarro, E.; Campillo, J.A.; Moya, R.; Pérez-Cárceles, M.D.; Luna, A.; Osuna, E.; Miras, M.; Muro, M.; et al. KIR2DL2/S2 and KIR2DS5 in alcoholic cirrhotic patients undergoing liver transplantation. Arch. Med. Sci. 2021, 17, 764–774. [Google Scholar]
  31. Vilches, C.; Parham, P. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 2002, 20, 217–251. [Google Scholar] [PubMed]
  32. Heidelbaugh, J.J.; Bruderly, M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. Am. Fam. Physician 2006, 74, 756–762. [Google Scholar] [PubMed]
  33. Demetris, A.J.; Batts, K.P.; Dhillon, A.P.; Ferrell, L.; Fung, J.; Geller, S.A.; Hart, J.; Hayry, P.; Hofmann, W.J.; Hubscher, S.; et al. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997, 25, 658–663. [Google Scholar]
  34. Mor, E.; Solomon, H.; Gibbs, J.F.; Holman, M.J.; Goldstein, R.M.; Husberg, B.; Gonwa, T.A.; Klintmalm, G.B. Acute cellular rejection following liver transplantation: Clinical pathologic features and effect on outcome. Semin. Liver Dis. 1992, 12, 28–40. [Google Scholar]
  35. Bolarín, J.M.; Pérez-Cárceles, M.D.; Hernández Del Rincón, J.P.; Luna, A.; Minguela, A.; Muro, M.; Legaz, I. Causes of Death and Survival in Alcoholic Cirrhosis Patients Undergoing Liver Transplantation: Influence of the Patient’s Clinical Variables and Transplant Outcome Complications. Diagnostics 2021, 11, 968. [Google Scholar]
  36. Legaz, I.; Bolarín, J.M.; Campillo, J.A.; Moya-Quiles, M.R.; Miras, M.; Muro, M.; Minguela, A.; Álvarez-López, M.R. Killer Cell Immunoglobulin-like Receptors (KIR) and Human Leucocyte Antigen C (HLA-C) Increase the Risk of Long-Term Chronic Liver Graft Rejection. Int. J. Mol. Sci. 2022, 23, 12155. [Google Scholar] [CrossRef]
  37. Spanier, T.B.; Klein, R.D.; Nasraway, S.A.; Rand, W.M.; Rohrer, R.J.; Freeman, R.B.; Schwaitzberg, S.D. Multiple organ failure after liver transplantation. Crit. Care Med. 1995, 23, 466–473. [Google Scholar]
  38. Thuluvath, P.J.; Thuluvath, A.J.; Hanish, S.; Savva, Y. Liver transplantation in patients with multiple organ failures: Feasibility and outcomes. J. Hepatol. 2018, 69, 1047–1056. [Google Scholar]
  39. Riera Romo, M. Cell death as part of innate immunity: Cause or consequence? Immunology 2021, 163, 399–415. [Google Scholar]
  40. Frostegård, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013, 11, 117. [Google Scholar]
  41. Brown, L.A.S.; Cook, R.T.; Jerrells, T.R.; Kolls, J.K.; Nagy, L.E.; Szabo, G.; Wands, J.R.; Kovacs, E.J. Acute and Chronic Alcohol Abuse Modulate Immunity. Alcohol. Clin. Exp. Res. 2006, 30, 1624–1631. [Google Scholar] [CrossRef] [PubMed]
  42. Medzhitov, R.; Janeway, C.J. Advances in immunology: Innate immunity. N. Engl. J. Med. 2000, 343, 338–344. [Google Scholar] [PubMed]
  43. Kovacs, E.J.; Messingham, K.A.N. Influence of alcohol and gender on immune response. Alcohol Res. Health 2002, 26, 257–263. [Google Scholar] [PubMed]
  44. Hou, Y.-F.; Zhang, Y.-C.; Jiao, Y.-L.; Wang, L.-C.; Li, J.-F.; Pan, Z.-L.; Yang, Q.-R.; Sun, H.-S.; Zhao, Y.-R. Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus 2010, 19, 20–26. [Google Scholar] [PubMed]
  45. Tozkır, J.D.; Tozkır, H.; Gürkan, H.; Dönmez, S.; Eker, D.; Pamuk, G.E.; Pamuk, Ö.N. The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis. Clin. Rheumatol. 2016, 35, 919–925. [Google Scholar] [CrossRef]
  46. O’Connor, G.M.; McVicar, D.W. The Yin-Yang of KIR3DL1/S1: Molecular mechanisms and cellular function. Crit. Rev. Immunol. 2013, 33, 203–218. [Google Scholar]
  47. Wendon, J.; Lee, W. Encephalopathy and cerebral edema in the setting of acute liver failure: Pathogenesis and management. Neurocrit. Care 2008, 9, 97–102. [Google Scholar] [CrossRef]
  48. Bernal, W.; Hall, C.; Karvellas, C.J.; Auzinger, G.; Sizer, E.; Wendon, J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007, 46, 1844–1852. [Google Scholar]
Diagnostics 13 01217 g001 550
Figure 1. Analysis of the frequency of KIR genes in causes of death in patients with and without ascites. (A) Deceased patients due to multiorgan failure. (B) Deceased patients due to sepsis. (C) Deceased patients due to GF.
Figure 1. Analysis of the frequency of KIR genes in causes of death in patients with and without ascites. (A) Deceased patients due to multiorgan failure. (B) Deceased patients due to sepsis. (C) Deceased patients due to GF.
Diagnostics 13 01217 g001
Diagnostics 13 01217 g002 550
Figure 2. Analysis of the frequency of KIR genes in the main causes of death in patients with and without encephalopathy. (A) Deceased patients due to multiorgan failure. (B) Deceased patients due to sepsis. (C) Deceased patients due to GF. * p = 0.018; OR = 2.124; 95% CI: 1.264–2.146, p value obtained by comparing encephalopathy-/KIR2D2DL5+ with encephalopathy+/KIR2D2DL5+ AC patients. (D) Comparison of the different causes of death in AC patients KIR3DL1+ with and without encephalopathy.
Figure 2. Analysis of the frequency of KIR genes in the main causes of death in patients with and without encephalopathy. (A) Deceased patients due to multiorgan failure. (B) Deceased patients due to sepsis. (C) Deceased patients due to GF. * p = 0.018; OR = 2.124; 95% CI: 1.264–2.146, p value obtained by comparing encephalopathy-/KIR2D2DL5+ with encephalopathy+/KIR2D2DL5+ AC patients. (D) Comparison of the different causes of death in AC patients KIR3DL1+ with and without encephalopathy.
Diagnostics 13 01217 g002
Diagnostics 13 01217 g003 550
Figure 3. Kaplan–Meier patient survival curves according to the main cause of death and KIR genes. (A–E) Kaplan–Meier patient survival curves according to the frequency of iKIRs (KIR2DL1+, KIR2DL2+, KIR2DL3+, KIR2DL5+, and KIR3DL1+). iKIR, inhibitory KIR; aKIR, activatory KIR. Other causes of deaths include; Lung edema, pharynx neoplasia, pancreatitis, pneumonia, chronic rejection, primary dysfunction, and HCV relapse.
Figure 3. Kaplan–Meier patient survival curves according to the main cause of death and KIR genes. (A–E) Kaplan–Meier patient survival curves according to the frequency of iKIRs (KIR2DL1+, KIR2DL2+, KIR2DL3+, KIR2DL5+, and KIR3DL1+). iKIR, inhibitory KIR; aKIR, activatory KIR. Other causes of deaths include; Lung edema, pharynx neoplasia, pancreatitis, pneumonia, chronic rejection, primary dysfunction, and HCV relapse.
Diagnostics 13 01217 g003
Diagnostics 13 01217 g004 550
Figure 4. Kaplan–Meier patient survival curves based on the main cause of death and KIR genes. (A) Kaplan–Meier patient survival curves according to the presence of KIR2DL3+. (B–F) Kaplan–Meier patient survival curves according to the presence of KIR2DS2+, KIR2DS3+, KIR2DS4+ and KIR2DS5+, KIR3DS1+.
Figure 4. Kaplan–Meier patient survival curves based on the main cause of death and KIR genes. (A) Kaplan–Meier patient survival curves according to the presence of KIR2DL3+. (B–F) Kaplan–Meier patient survival curves according to the presence of KIR2DS2+, KIR2DS3+, KIR2DS4+ and KIR2DS5+, KIR3DS1+.
Diagnostics 13 01217 g004
Table
Table 1. Baseline demographic, clinical, and biochemical characteristics of the male AC patients were analyzed in this study.
Table 1. Baseline demographic, clinical, and biochemical characteristics of the male AC patients were analyzed in this study.
Total AC Patients
N = 164, n (%)
Recipient
 Mean age * (mean years ± SD)54.3 ± 6.9
 Sex (male/female)150 (91.4)/14 (8.6)
Ascites+
Mean age		118 (71.9)
54.2 ± 1.3
Encephalopathy+
Mean age		39 (23.7)
56.7 ± 2.0
Causes of death
 Sepsis39 (23.7)
 Graft failure32 (19.5)
 Multiorgan failure29 (17.7)
 Others **64 (39.1)
AC, alcoholic cirrhosis; N, total number of individuals; n, number of patients in each group; SD, standard deviation. * The mean values were analyzed (mean value ± SD) in all cases. ** Other causes of death include cardiac arrest, digestive bleeding, edema lung, metastasis, pancreatitis, pneumonia, primary dysfunction, and viral relapse.
Table
Table 2. Frequency of KIR genes in AC patients with different causes of death.
Table 2. Frequency of KIR genes in AC patients with different causes of death.
Causes of Death
Multiorgan
Failure (MF)
(N = 29)		Sepsis (S)
(N = 39)		Graft Failure (GF)
(N = 32)
KIR Genesn (%)n (%)n (%)
iKIRs
 KIR2DL1+/S1−19 (65.5)23 (58.9)22 (68.7)
 KIR2DL2+22 (75.8) a21 (53.8)14 (43.7)
 KIR2DL3+26 (89.6)36 (92.3)30 (93.7)
 KIR3DL1+24 (82.7)31 (79.4)30 (93.7)
aKIRs
 KIR2DS1+11 (37.9)13 (33.3)10 (31.2)
 KIR2DS2+22 (75.8) b20 (51.2) c14 (43.7)
 KIR2DS3+9 (31.0)7 (17.9)10 (31.2)
 KIR2DS4+24 (82.7)31 (79.4)30 (93.7)
 KIR2DS5+11 (37.9)12 (30.7)10 (31.2)
N is the total number of individuals; n is the number of individuals with a KIR gene. MF; Multiorgan failure; S; Sepsis, GF; Graft failure. All comparisons were made using the 2-tailed Fisher’s exact test. a OR = 0.247; 95% CI: 0.082–0.744, p = 0.018; p value obtained by comparing MF KIR2DL2+ patients with GF KIR2DL2+ patients. b OR =2.986; 95% CI: 1.037–8.594, p = 0.047; p value obtained by comparing MF KIR2DS2+ patients with GF KIR2DS2+ patients. c OR = 4.041; 95% CI: 1.344–12.146, p = 0.018; p value obtained by comparing MF KIR2DS2+ patients with GF KIR2DS2+ patients.
Table
Table 3. Logistic regression multivariable analysis for main causes of death.
Table 3. Logistic regression multivariable analysis for main causes of death.
WaldpOR95% CI
LowerUpper
Sepsis
 KIR2DL20.7850.3760.4320.0672.768
 KIR2DL50.0000.9961.0070.06415.856
 KIR3DL14.0560.0440.0250.0010.906
 KIR2DS10.9890.3200.1760.0065.413
 Ascites1.3710.2423.4320.43627.042
 Encephalopathy0.1480.7000.6980.1124.364
Graft failure
 KIR2DL21.5800.2090.3160.0521.907
 KIR2DL50.1410.7071.6360.12621.272
 KIR3DL10.1170.7321.8120.06054.295
 KIR2DS10.0640.8011.4680.07528.890
 Ascites2.5170.1130.1170.0081.658
 Encephalopathy1.0680.3012.8250.39420.245
Multiorgan failure
 KIR2DL23.1480.0768.9110.79599.821
 KIR2DL52.6520.1030.1220.0101.535
 KIR3DL11.0080.3150.1440.0036.333
 Ascites0.1900.6631.6210.18414.241
 Encephalopathy1.3590.2240.2700.0302.443
OR, an odds ratio with a confidence interval (CI) of 95%. p-values marked in bold are statistically significant (p < 0.05).
Table
Table 4. Cox regression multivariable analysis for AC patients’ survival.
Table 4. Cox regression multivariable analysis for AC patients’ survival.
WaldpOR95% CI
LowerUpper
 Age0.7190.3962.0330.39410.489
 KIR3DL13.4430.0343.9790.92517.110
 KIR2DS13.5200.0412.7360.9567.831
 KIR2DS30.0880.0261.1400.4792.715
 KIR2DS40.0640.8011.4680.07518.890
OR. odds ratio with a confidence interval (CI) of 95%. p-values marked in bold are statistically significant at p < 0.1.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Morales, R.; Bolarín, J.M.; Muro, M.; Legaz, I. Presence of KIR2DL2/S2, KIR2DL5, and KIR3DL1 Molecules in Liver Transplant Recipients with Alcoholic Cirrhosis Could Be Implicated in Death by Graft Failure. Diagnostics 2023, 13, 1217. https://doi.org/10.3390/diagnostics13071217

AMA Style

Morales R, Bolarín JM, Muro M, Legaz I. Presence of KIR2DL2/S2, KIR2DL5, and KIR3DL1 Molecules in Liver Transplant Recipients with Alcoholic Cirrhosis Could Be Implicated in Death by Graft Failure. Diagnostics. 2023; 13(7):1217. https://doi.org/10.3390/diagnostics13071217

Chicago/Turabian Style

Morales, Raquel, José Miguel Bolarín, Manuel Muro, and Isabel Legaz. 2023. "Presence of KIR2DL2/S2, KIR2DL5, and KIR3DL1 Molecules in Liver Transplant Recipients with Alcoholic Cirrhosis Could Be Implicated in Death by Graft Failure" Diagnostics 13, no. 7: 1217. https://doi.org/10.3390/diagnostics13071217

APA Style

Morales, R., Bolarín, J. M., Muro, M., & Legaz, I. (2023). Presence of KIR2DL2/S2, KIR2DL5, and KIR3DL1 Molecules in Liver Transplant Recipients with Alcoholic Cirrhosis Could Be Implicated in Death by Graft Failure. Diagnostics, 13(7), 1217. https://doi.org/10.3390/diagnostics13071217

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop